Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded dual-centre read

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1198-1203

  Furth, C ^a   Amthauer, H ^a,b   Hautzel, H ^c   Steffen, I G ^a,b   Ruf, J ^a   Schiefer, J ^a   Schonberger S ^d   Henze, G ^b   Grandt, R ^c   Hundsdoerfer, P ^b   Dietlein, M ^e   Kobe, C ^e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Childhood; FDG PET; Hodgkin's lymphoma; Response assessment; Response criteria; Therapy monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HODGKIN DISEASE; HUMAN; INTERIM POSITRON EMISSION TOMOGRAPHY; INTERRATER RELIABILITY; MALE; MEDIASTINUM; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RATING SCALE; SENSITIVITY ANALYSIS;

EID: 79955504718     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq557     Document Type: Article

References (33)

1. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 17: 1-4.
2. Korholz D, Claviez A, Hasenclever D et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156.
3. Engert A, Dreyling M. Hodgkin's lymphoma: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (SUPPL 2): ii65-ii66.
4. Dörffel W, Lüders H, Rühl U et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215: 139-145.
5. Korholz D, Kluge R, Wickmann L et al. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence: consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26: 489-493.
6. Bhatia S, Robinson LL, Oberlin O et al. Breast cancer and other second neoplasm after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
7. Bhatia S, Yasui Y, Robinson LL et al. High risk of subsequent neoplasm continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 23: 4386-4394.
8. Foss-Abrahamsen A, Andersen A, Nome O et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 2002; 13: 1786-1791.
9. van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-497.
10. Green DM, Hyland A, Barcos MP et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000; 18: 1492-1499.
11. Schellong G, Riepenhausen M. Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 2004; 216: 364-369.
12. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
13. Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-481.
14. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.
15. Furth C, Steffen IG, Amthauer H et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009; 27: 4385-4391.
16. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168.
17. Hutchings M, Loft A, Hansen M et al. FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
18. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3389-3994.
19. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
20. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours, 7th edition. New York: John Wiley & Sons 2009.
21. Furth C, Denecke T, Steffen I et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J Pediatr Hematol Oncol 2006; 28: 501-512.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
23. Hofman MS, Smeeton NC, Rankin SC et al. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med 2009; 50: 1594-1597.
24. Fletcher BD, Glicksman AS, Gieser P. Interobserver variability in the detection of cervical-thoracic Hodgkin's disease by computed tomography. J Clin Oncol 1999; 17: 2153-3159.
25. Zijlstra JM, Comans EF, van Lingen A et al. FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study. Nucl Med Commun 2007; 28: 798-803.
26. Horning SJ, Juweid ME, Schöder H et al. Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010; 28: 775-777.
27. Markova J, Kobe C, Skopalova M et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advancedstage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009; 20: 1270-1274.
28. Mauz-Körholz C, Hasenclever D, Dörffel, W et al. Procarbazine-free OEPACOPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010 July 12. [Epub ahead of print].
29. Brepoels L, Stroobants S. PET scanning and prognosis in Hodgkin's lymphoma. Curr Opin Oncol 2008; 20: 509-516.
30. Petrausch U, Samaras P, Veit-Haibach P et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow up. Ann Oncol 2009 February 05. [Epub ahead of print].
31. Hutching M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50: 21S-30S.
32. Kobe C, Dietlein M, Mauz-Korholz C et al. FDG-PET in Hodgkin lymphoma. Nuklearmedizin 2008; 47: 235-238.
33. Boellaard R, O'Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.